Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02415842 · ClinicalTrials.gov registry record
A Laboratory Evaluation of the Humoral Immune Response in Adults and Children to the H1 Hemagglutinin (HA) Stalk Domain and Other Influenza A Virus Protein Epitopes, After Administration of GlaxoSmithKline (GSK) Biologicals' Pandemic Influenza Vaccines
A clinical trial, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- 414
- Enrollment target
NCT02415842 is a clinical trial that has completed, run by GlaxoSmithKline. The registered enrollment target is 414 participants.
The verdict
NCT02415842 has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- 414 participants
- Enrollment target
Study Summary
The purpose of this exploratory, retrospective laboratory study is to assess the humoral immune response to H1 hemagglutinin stalk domain and other influenza A virus protein epitopes following administration, in adults and children, of GSK Biologicals' adjuvanted and unadjuvanted pandemic influenza vaccines, using archived serum samples from previously completed clinical trials.
Interventions
- OTHER Serum samples
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 414 participants |
| Start Date | 2015-10-26 |
| Est. Completion | 2018-02-16 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02415842
The ClinicalTrials.gov registry entry for NCT02415842 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 414 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Serum samples is the first listed.
NCT02415842 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02415842 about?
NCT02415842 is a clinical study titled "A Laboratory Evaluation of the Humoral Immune Response in Adults and Children to the H1 Hemagglutinin (HA) Stalk Domain and Other Influenza A Virus Protein Epitopes, After Administration of GlaxoSmithKline (GSK) Biologicals' Pandemic Influenza Vaccines". The purpose of this exploratory, retrospective laboratory study is to assess the humoral immune response to H1 hemagglutinin stalk domain and other influenza A virus protein epitopes following administration, in adults and children, of GSK Biologicals' adjuvanted and unadjuvanted pandemic influenza ...
What is the current status of trial NCT02415842?
This trial is currently completed. The enrollment target is 414 participants. The study started on 2015-10-26. Estimated completion is 2018-02-16.
What interventions are being tested in trial NCT02415842?
The interventions under investigation include: Serum samples (OTHER).
Who is sponsoring clinical trial NCT02415842?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.